Inactive Instrument

Company Aerie Pharmaceuticals, Inc.

Equities

AERI

US00771V1089

Pharmaceuticals

Business Summary

Aerie Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The Company's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.

Number of employees: 376

Managers

Managers TitleAgeSince
Chief Executive Officer 58 22-11-20
Compliance Officer - -
Chief Tech/Sci/R&D Officer - 22-02-28
Chief Tech/Sci/R&D Officer - 20-02-02
Corporate Officer/Principal - -
Corporate Officer/Principal - 21-07-14
Sales & Marketing - -
Human Resources Officer - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 54 22-11-20
Chairman 57 22-11-20
Director/Board Member - 22-11-20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 49,417,407 49,245,119 ( 99.65 %) 0 99.65 %

Company contact information

Aerie Pharmaceuticals, Inc.

6201 South Freeway

76134, Forth Worth

+919 237 5300

http://www.aeriepharma.com
address Aerie Pharmaceuticals, Inc.(AERI)